IVA

Inventiva SA ADR · NASDAQ

Sector Health Technology
Industry Biotechnology
Website inventivapharma.com
Employees(FY) 117
ISIN US46124U1079

Performance

+3.79%

+4.18%

+17.09%

-27.78%

-39.33%

YTD

-31.89%

Profile

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of mucopolysaccharidoses type VI disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

Advanced Technical Analysis

Technical Analysis of IVA 2024-11-20

The stock exhibits a bullish sentiment overall, driven by a strong Moving Average Score of 76, while the Technical Score of 63 further supports this positive outlook; however, the neutral Oscillators Score of 50 suggests a potential consolidation phase that investors should monitor closely.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of IVA

Stock Rank

Recent News & Updates

2024-11-15 03:00
Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting late-breaker session(Globenewswire)
2024-10-30 04:00
Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH(Globenewswire)
2024-10-20 20:30
Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting 2024(Globenewswire)
2024-10-14 01:45
Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants(Globenewswire)
2024-10-13 14:35
Inventiva announces Filing of 2024 Half-Year Report Conditions for Accessing or Consulting the Report(Globenewswire)
2024-10-13 14:30
Inventiva announces financing of up to 348 million to advance the NATiV3 Phase 3 MASH study(Globenewswire)
2024-09-25 04:00
Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results(Globenewswire)
2024-07-31 04:00
Inventiva Reports Preliminary 2024 First-Half Financial Information(Globenewswire)
2024-07-25 04:00
Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor(Globenewswire)
2024-07-18 23:30
Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux(Globenewswire)
2024-07-17 14:30
Inventiva announces a 20.1 million issuance of royalty certificates(Globenewswire)
2024-07-05 04:00
Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position(Globenewswire)
2024-06-21 04:05
Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 20 June 2024(Yahoo Finance)
2024-06-21 04:00
Results of the votes of the Combined Shareholders' General Meeting of June 20, 2024(Globenewswire)
2024-06-17 21:35
Down -27.95% in 4 Weeks, Here's Why You Should You Buy the Dip in Inventiva (IVA)(Zacks)
2024-05-29 14:30
Statement of total voting rights and shares forming the companys share capital as of May 13, 2024(Yahoo Finance)
2024-05-29 14:30
Combined General Meeting of June 20, 2024 - Availability of the preparatory documents(Globenewswire)
2024-05-22 04:00
Inventiva announces two scientific presentations at the EASL International Liver Congress 2024(Globenewswire)
2024-05-21 04:00
Inventiva reports 2024 First Quarter Financial Information and provides a corporate update(Globenewswire)
2024-05-16 04:00
Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH(Globenewswire)
2024-05-13 04:08
Why Is Inventiva's Stock Trading Higher on Monday?(Yahoo Finance)
2024-05-12 14:30
Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor(Globenewswire)
2024-04-03 04:00
Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F(Globenewswire)
2024-04-01 02:17
Inventiva S.A. (NASDAQ:IVA) Q4 2023 Earnings Call Transcript(Insidermonkey)
2024-03-27 15:00
Inventiva announces the nomination of Andre Turenne as Director(Globenewswire)
2024-03-27 04:00
Inventiva reports its 2023 full-year results(Globenewswire)
2024-03-22 04:00
Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results(Globenewswire)
2024-03-18 04:00
Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D(Globenewswire)
2024-03-13 04:00
Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D(Globenewswire)
2024-03-07 03:00
Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed(Globenewswire)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.